These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 20102348

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization.
    Tong JP, Chan WM, Liu DT, Lai TY, Choy KW, Pang CP, Lam DS.
    Am J Ophthalmol; 2006 Mar; 141(3):456-62. PubMed ID: 16490490
    [Abstract] [Full Text] [Related]

  • 4. Changes in aqueous vascular endothelial growth factor and pigment epithelial-derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related macular degeneration or pathologic myopia.
    Chan WM, Lai TY, Chan KP, Li H, Liu DT, Lam DS, Pang CP.
    Retina; 2008 Oct; 28(9):1308-13. PubMed ID: 18728623
    [Abstract] [Full Text] [Related]

  • 5. Aqueous humor levels of vascular endothelial growth factor before and after intravitreal bevacizumab in type 3 versus type 1 and 2 neovascularization. A prospective, case-control study.
    dell'Omo R, Cassetta M, dell'Omo E, di Salvatore A, Hughes JM, Aceto F, Porcellini A, Costagliola C.
    Am J Ophthalmol; 2012 Jan; 153(1):155-61.e2. PubMed ID: 21861975
    [Abstract] [Full Text] [Related]

  • 6. Associations of inflammatory cytokines with choroidal neovascularization in highly myopic eyes.
    Yamamoto Y, Miyazaki D, Sasaki S, Miyake K, Kaneda S, Ikeda Y, Baba T, Yamasaki A, Noguchi Y, Inoue Y.
    Retina; 2015 Feb; 35(2):344-50. PubMed ID: 25289657
    [Abstract] [Full Text] [Related]

  • 7. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with amd after bevacizumab treatment.
    Roh MI, Kim HS, Song JH, Lim JB, Koh HJ, Kwon OW.
    Retina; 2009 Apr; 29(4):523-9. PubMed ID: 19262441
    [Abstract] [Full Text] [Related]

  • 8. The landscape of angiogenesis and inflammatory factors in eyes with myopic choroidal neovascularization before and after anti-VEGF injection.
    Wang T, Lian P, Zhan J, Li Y, Liu B, Zhao X, Wu Q, Li H, Lu L, Chen S.
    Cytokine; 2024 Jul; 179():156640. PubMed ID: 38735245
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results.
    Ikuno Y, Sayanagi K, Soga K, Sawa M, Tsujikawa M, Gomi F, Tano Y.
    Am J Ophthalmol; 2009 Jan; 147(1):94-100.e1. PubMed ID: 18774550
    [Abstract] [Full Text] [Related]

  • 11. Aqueous humor levels of vascular endothelial growth factor in retinitis pigmentosa.
    Salom D, Diaz-Llopis M, García-Delpech S, Udaondo P, Sancho-Tello M, Romero FJ.
    Invest Ophthalmol Vis Sci; 2008 Aug; 49(8):3499-502. PubMed ID: 18326689
    [Abstract] [Full Text] [Related]

  • 12. Vascular endothelial growth factor in patients with exudative age-related macular degeneration treated with ranibizumab.
    Muether PS, Hermann MM, Viebahn U, Kirchhof B, Fauser S.
    Ophthalmology; 2012 Oct; 119(10):2082-6. PubMed ID: 22920670
    [Abstract] [Full Text] [Related]

  • 13. Effects of intravitreally injected bevacizumab on vascular endothelial growth factor in fellow eyes.
    Matsuyama K, Ogata N, Matsuoka M, Wada M, Nishimura T, Takahashi K.
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):379-83. PubMed ID: 21810018
    [Abstract] [Full Text] [Related]

  • 14. Levels of erythropoietin and vascular endothelial growth factor in surgery-required advanced neovascular glaucoma eyes before and after intravitreal injection of bevacizumab.
    Zhou M, Chen S, Wang W, Huang W, Cheng B, Ding X, Zhang X.
    Invest Ophthalmol Vis Sci; 2013 Jun 04; 54(6):3874-9. PubMed ID: 23674760
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
    Yoon JU, Kim YM, Lee SJ, Byun YJ, Koh HJ.
    Retina; 2012 May 04; 32(5):949-55. PubMed ID: 22534553
    [Abstract] [Full Text] [Related]

  • 17. Correlation of macular choroidal thickness with concentrations of aqueous vascular endothelial growth factor in high myopia.
    Chen W, Song H, Xie S, Han Q, Tang X, Chu Y.
    Curr Eye Res; 2015 Mar 04; 40(3):307-13. PubMed ID: 25300046
    [Abstract] [Full Text] [Related]

  • 18. Retinal vascular changes and aqueous humor cytokines changes after aflibercept intravitreal injection in treatment-naïve myopic choroidal neovascularization.
    Di Antonio L, Toto L, Mastropasqua A, Brescia L, Erroi E, Lamolinara A, Di Nicola M, Mastropasqua L.
    Sci Rep; 2018 Oct 23; 8(1):15631. PubMed ID: 30353107
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of bevacizumab and its effect on vascular endothelial growth factor after intravitreal injection of bevacizumab in macaque eyes.
    Miyake T, Sawada O, Kakinoki M, Sawada T, Kawamura H, Ogasawara K, Ohji M.
    Invest Ophthalmol Vis Sci; 2010 Mar 23; 51(3):1606-8. PubMed ID: 19875666
    [Abstract] [Full Text] [Related]

  • 20. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization.
    Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Tübingen Bevacizumab Study Group, Grisanti S.
    Ophthalmology; 2008 Oct 23; 115(10):1750-5, 1755.e1. PubMed ID: 18708261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.